Alzheimer’s testing advances helping patients get earlier treatment
Alzheimer’s Association Launches (re)think your brain to Drive Early Action on Brain Health
The Alzheimer’s Association today announced the launch of (re)think your brain™, a new science-based initiative designed to move people from brain health awareness to action. The initiative expands how people understand and care for their brains and introduces the (re)think your brain 6-Step Challenge, a step-by-step guide with proven practical actions people can start right away to help support brain health and cognitive function.
According to the Alzheimer’s Association 2026 Alzheimer’s Disease Facts and Figures report, nearly nine in 10 U.S. adults say maintaining brain health as they age is very important, and 99% say it is as important as physical health. Yet only 9% say they know how to maintain their brain health, revealing a clear gap between awareness and action.
Read more about this HERE
A new study says Alzheimer’s treatments don’t work. My life says otherwise.
I was one of the participants in a clinical trial that led to the approval of new Alzheimer’s treatments in 2024.
This treatment improved my memory and mental sharpness, giving me more good years with the people I love: my husband Brent, my six children, 22 grandchildren, and two great-grandchildren.
I’m grateful that my grandchildren get to know me not as an Alzheimer’s patient, but just as a grandmother who is capable of talking to them, teaching recipes and making memories.
That’s why I was saddened to see a new review claiming that the medicines have little benefit. It contradicted the reality that I lived and felt like an attempt to stamp out hope for the thousands of patients receiving Alzheimer’s diagnoses today.
Read more HERE
People living with dementia and their families need clear guidance when weighing choices of new Alzheimer’s treatments
Guided by our Medical & Scientific Advisory Panel (MSAP), Alzheimer’s Disease International’s position is that people making decisions about treatment benefit from information that is specific, balanced, and transparent. This includes an honest discussion of the potential advantages, the limitations, and the uncertainties of each approved therapy. Approaches that combine results from multiple drugs with very different characteristics can unintentionally obscure both signs of benefit and risks, precisely at a time when people affected by MCI (Mild Cognitive Impairment) or by dementia due to Alzheimer’s disease and carers are seeking practical guidance.
Read more HERE
Can Walking Reduce the Risk of Alzheimer’s Disease?
- A 10-year study showed that APOE e4 carriers experience faster cognitive decline than APOE e2 and e3 carriers.
- Greater walking time appeared to benefit cognitive performance for female APOE e2 and e3 carriers.
- In males, walking time and APOE status were not as strongly associated with cognition.
- Maintaining walking time over 10 years was associated with slower cognitive decline among APOE e4 carriers.
Read more HERE